Paper42657158
Mepolizumab reduces systemic corticosteroid-related toxicities and healthcare burden in patients with eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome: a retrospective database study.
Pongdee T and 8 others. Front Allergy, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Mepolizumab reduces systemic corticosteroid-related toxicities and healthcare burden in patients with eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome: a retrospective database study. Papers, record 42657158. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42657158
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Mepolizumab reduces systemic corticosteroid-related toxicities and healthcare burden in patients with eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome: a retrospective database study.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References44
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36927642 | EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. | Ann Rheum Dis | 2024 | https://conductscience.org/library/papers/36927642 | PubMed |
| 2 | 40656763 | Burden of hypereosinophilic syndromes in the United States: Patients' perspective. | J Allergy Clin Immunol Glob | 2025 | https://conductscience.org/library/papers/40656763 | PubMed |
| 3 | 36530646 | Insights from Social Media on the Patient Experience of Living With Rare Eosinophil-Driven Diseases. | J Patient Exp | 2022 | https://conductscience.org/library/papers/36530646 | PubMed |
| 4 | 37064032 | Mepolizumab therapy improves the most bothersome symptoms in patients with hypereosinophilic syndrome. | Front Med (Lausanne) | 2023 | https://conductscience.org/library/papers/37064032 | PubMed |
| 5 | 41242921 | Mepolizumab improves health-related quality of life in patients with hypereosinophilic syndrome. | Eur J Intern Med | 2026 | https://conductscience.org/library/papers/41242921 | PubMed |
| 6 | 37605658 | Retrospective Analysis of the Burden of Illness of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Versus Asthma in Commercially Insured US Patients. | Cureus | 2023 | https://conductscience.org/library/papers/37605658 | PubMed |
| 7 | 34389506 | Safety and Efficacy of Mepolizumab in Hypereosinophilic Syndrome: An Open-Label Extension Study. | J Allergy Clin Immunol Pract | 2021 | https://conductscience.org/library/papers/34389506 | PubMed |
| 8 | 38532489 | Real-world association between systemic corticosteroid exposure and complications in US patients with severe asthma. | Allergy Asthma Clin Immunol | 2024 | https://conductscience.org/library/papers/38532489 | PubMed |
| 9 | 37419574 | HES and EGPA: Two Sides of the Same Coin. | Mayo Clin Proc | 2023 | https://conductscience.org/library/papers/37419574 | PubMed |
| 10 | 26475367 | Hypereosinophilic Syndrome. | Clin Rev Allergy Immunol | 2016 | https://conductscience.org/library/papers/26475367 | PubMed |
| 11 | 37161084 | Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis. | Nat Rev Rheumatol | 2023 | https://conductscience.org/library/papers/37161084 | PubMed |
| 12 | 40886121 | Discontinuation of Oral Glucocorticoids and Achievement of Remission in Patients With Eosinophilic Granulomatosis With Polyangiitis Treated With Benralizumab or Mepolizumab. | ACR Open Rheumatol | 2025 | https://conductscience.org/library/papers/40886121 | PubMed |
| 13 | 39508562 | Real-world safety and effectiveness of mepolizumab for patients with eosinophilic granulomatosis with polyangiitis in Japan: Long-term observation of the MARS study. | Mod Rheumatol | 2025 | https://conductscience.org/library/papers/39508562 | PubMed |
| 14 | 40499922 | The 2025 British Society for Rheumatology management recommendations for ANCA-associated vasculitis. | Rheumatology (Oxford) | 2025 | https://conductscience.org/library/papers/40499922 | PubMed |
| 15 | 32956756 | Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial. | J Allergy Clin Immunol | 2020 | https://conductscience.org/library/papers/32956756 | PubMed |
| 16 | 18344568 | Treatment of patients with the hypereosinophilic syndrome with mepolizumab. | N Engl J Med | 2008 | https://conductscience.org/library/papers/18344568 | PubMed |
| 17 | 42367662 | Patient perspectives on glucocorticoid-associated complications and sequelae in ANCA-associated vasculitis. | EULAR Rheumatol Open | 2025 | https://conductscience.org/library/papers/42367662 | PubMed |
| 18 | 29055500 | Long-term Systemic Corticosteroid Exposure: A Systematic Literature Review. | Clin Ther | 2017 | https://conductscience.org/library/papers/29055500 | PubMed |
| 19 | 25205825 | Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. | Rheumatology (Oxford) | 2015 | https://conductscience.org/library/papers/25205825 | PubMed |
| 20 | 42367648 | Patients' perspectives of eosinophilic granulomatosis with polyangiitis within the context of a clinical trial. | EULAR Rheumatol Open | 2025 | https://conductscience.org/library/papers/42367648 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| IL5 | 3567 | PubTator's text mining | https://conductscience.org/library/genes/3567 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42657158
GET https://conductscience.org/api/papers/v1/42657158/references?page=2